thepharmaletter.com
FDA nod for Tremfya as J&J builds on Stelara transition
An FDA approval means a new biologic option (guselkumab/Tremfya) is available for adults with moderately to severely active Crohn’s disease and may change prescribing choices. The approval highlights a dosing flexibility (IV and subcutaneous induction) that could matter for how treatment is given.
It also reflects commercial shifts that can affect availability and insurance coverage.
Adults with Crohn’s disease, patients considering or on biologic therapy, gastroenterologists and IBD clinicians, and researchers tracking IBD drug development or market access.
What To Know
The FDA has approved Tremfya (guselkumab) for adults with moderately to severely active Crohn’s disease and the article notes this expands the drug’s role as J&J manages transition from Stelara (ustekinumab).
Tremfya is described as the first IL-23 inhibitor in the US cleared to offer both intravenous and subcutaneous induction dosing options for Crohn’s disease.
What To Know This is a regulatory approval story — Tremfya (an IL-23 inhibitor) now has FDA clearance for adults with moderately to severely active Crohn’s disease, including both IV and self-administered subcutaneous induction dosing options according to the report.
The piece frames the approval in commercial terms for Johnson & Johnson as it seeks to offset declining Stelara sales. The article appears in a pharma-industry news outlet and focuses on approval and business strategy rather than patient-level clinical guidance.
If you want details about who qualifies for treatment, how dosing works, efficacy, or safety compared with other options, consult the prescribing information or discuss with a treating clinician.
This is a regulatory-news item from a pharmaceutical industry publication; it summarizes the FDA decision and commercial implications. It does not provide clinical trial data, detailed safety or efficacy results, or prescribing guidance. Patients should refer to official FDA materials and product labeling or speak with their clinician for individual treatment decisions.
